Home Healthcare Healthcare Services Central lab market

Central lab market Size, Share & Trends Analysis Report By Service Type (Biomarker Services, Genetic and Genomic Services, Microbiology Services, Clinical Chemistry and Hematology Services, Others), By Therapeutic Area (Oncology, Cardiovascular Diseases, Infectious Diseases, Neurology, Metabolic and Endocrine Disorders, Others), By End User (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Medical Device Companies, Others), By Clinical Trial Phase (Phase I, Phase II, Phase III, Phase IV) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: September 18, 2026 | Author: Debashree Bora | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Central lab market, By Service Type 2022-2034 (USD MILLION/ Units)
    1. Biomarker Services
    2. Genetic and Genomic Services
    3. Microbiology Services
    4. Clinical Chemistry and Hematology Services
    5. Histopathology and Anatomic Pathology Services
    6. Other Central Laboratory Services
  2. Central lab market, By Therapeutic Area 2022-2034 (USD MILLION/ Units)
    1. Oncology
    2. Cardiovascular Diseases
    3. Infectious Diseases
    4. Neurology
    5. Metabolic and Endocrine Disorders
    6. Immunology and Inflammation
    7. Others
  3. Central lab market, By End User 2022-2034 (USD MILLION/ Units)
    1. Pharmaceutical Companies
    2. Biotechnology Companies
    3. Contract Research Organizations
    4. Medical Device Companies
    5. Academic and Research Institutions
  4. Central lab market, By Clinical Trial Phase 2022-2034 (USD MILLION/ Units)
    1. Phase I
    2. Phase II
    3. Phase III
    4. Phase IV
  5. Regional Central lab market
    1. North America
      1. North America Central lab market By Service Type 2022-2034 (USD MILLION/ Units)
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
      2. North America Central lab market By Therapeutic Area 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Cardiovascular Diseases
        3. Infectious Diseases
        4. Neurology
        5. Metabolic and Endocrine Disorders
        6. Immunology and Inflammation
        7. Others
      3. North America Central lab market By End User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Biotechnology Companies
        3. Contract Research Organizations
        4. Medical Device Companies
        5. Academic and Research Institutions
      4. North America Central lab market By Clinical Trial Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      5. U.S.
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      6. Canada
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
    2. Europe
      1. Europe Central lab market By Service Type 2022-2034 (USD MILLION/ Units)
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
      2. Europe Central lab market By Therapeutic Area 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Cardiovascular Diseases
        3. Infectious Diseases
        4. Neurology
        5. Metabolic and Endocrine Disorders
        6. Immunology and Inflammation
        7. Others
      3. Europe Central lab market By End User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Biotechnology Companies
        3. Contract Research Organizations
        4. Medical Device Companies
        5. Academic and Research Institutions
      4. Europe Central lab market By Clinical Trial Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      5. U.K.
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      6. Germany
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      7. France
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      8. Spain
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      9. Italy
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      10. Russia
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      11. Nordic
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      12. Benelux
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      13. Rest of Europe
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
    3. APAC
      1. APAC Central lab market By Service Type 2022-2034 (USD MILLION/ Units)
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
      2. APAC Central lab market By Therapeutic Area 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Cardiovascular Diseases
        3. Infectious Diseases
        4. Neurology
        5. Metabolic and Endocrine Disorders
        6. Immunology and Inflammation
        7. Others
      3. APAC Central lab market By End User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Biotechnology Companies
        3. Contract Research Organizations
        4. Medical Device Companies
        5. Academic and Research Institutions
      4. APAC Central lab market By Clinical Trial Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      5. China
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      6. Korea
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      7. Japan
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      8. India
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      9. Australia
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      10. Taiwan
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      11. South East Asia
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      12. Rest of Asia-Pacific
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
    4. Middle East and Africa
      1. Middle East and Africa Central lab market By Service Type 2022-2034 (USD MILLION/ Units)
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
      2. Middle East and Africa Central lab market By Therapeutic Area 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Cardiovascular Diseases
        3. Infectious Diseases
        4. Neurology
        5. Metabolic and Endocrine Disorders
        6. Immunology and Inflammation
        7. Others
      3. Middle East and Africa Central lab market By End User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Biotechnology Companies
        3. Contract Research Organizations
        4. Medical Device Companies
        5. Academic and Research Institutions
      4. Middle East and Africa Central lab market By Clinical Trial Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      5. UAE
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      6. Turkey
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      7. Saudi Arabia
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      8. South Africa
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      9. Egypt
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      10. Nigeria
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      11. Rest of MEA
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
    5. LATAM
      1. LATAM Central lab market By Service Type 2022-2034 (USD MILLION/ Units)
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
      2. LATAM Central lab market By Therapeutic Area 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Cardiovascular Diseases
        3. Infectious Diseases
        4. Neurology
        5. Metabolic and Endocrine Disorders
        6. Immunology and Inflammation
        7. Others
      3. LATAM Central lab market By End User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Biotechnology Companies
        3. Contract Research Organizations
        4. Medical Device Companies
        5. Academic and Research Institutions
      4. LATAM Central lab market By Clinical Trial Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      5. Brazil
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      6. Mexico
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      7. Argentina
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      8. Chile
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      9. Colombia
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
      10. Rest of LATAM
        1. Biomarker Services
        2. Genetic and Genomic Services
        3. Microbiology Services
        4. Clinical Chemistry and Hematology Services
        5. Histopathology and Anatomic Pathology Services
        6. Other Central Laboratory Services
        7. Oncology
        8. Cardiovascular Diseases
        9. Infectious Diseases
        10. Neurology
        11. Metabolic and Endocrine Disorders
        12. Immunology and Inflammation
        13. Others
        14. Pharmaceutical Companies
        15. Biotechnology Companies
        16. Contract Research Organizations
        17. Medical Device Companies
        18. Academic and Research Institutions
        19. Phase I
        20. Phase II
        21. Phase III
        22. Phase IV
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.